Paliperidon Ratiopharm (Paliperidone Palmitate)

Paliperidone palmitate is an atypical antipsychotic used in the management of schizophrenia and related psychotic disorders.

• Schizophrenia: helps maintain symptom control and reduces risk of relapse when given as a monthly injection.
• Schizoaffective disorder: contributes to stabilization of mood and psychotic symptoms.
• Bipolar I disorder (maintenance): used as an adjunct to mood stabilisers to prevent manic or depressive episodes.
• Acute psychotic episodes (adjunct): may be added to oral therapy to achieve faster symptom control.
• Long‑term maintenance therapy: provides consistent plasma levels, improving adherence.
• Relapse prevention: reduces hospital readmission rates in stabilized patients.

• Paliperidone palmitate is a long‑acting ester of paliperidone that, after intramuscular administration, is slowly hydrolysed to release paliperidone. The active moiety antagonises dopamine D2 and serotonin 5‑HT2A receptors, modulating neurotransmission in pathways implicated in psychosis and mood regulation. This receptor blockade reduces positive psychotic symptoms and stabilises mood without causing excessive dopamine depletion.

Paliperidone palmitate may cause a range of adverse reactions, most of which are dose‑dependent and often resolve with continued therapy.

Common Side Effects

• Injection site pain or erythema
• Headache
• Drowsiness or somnolence
• Weight gain
• Restlessness (akathisia)
• Constipation

Serious or Rare Side Effects

• Neuroleptic malignant syndrome
• Tardive dyskinesia
• Severe orthostatic hypotension
• Hyperglycaemia or new‑onset diabetes
• Seizures
• Elevated prolactin with galactorrhoea or menstrual disturbances

When prescribing Paliperidone palmitate, clinicians should consider several safety aspects.

• Cardiovascular assessment: evaluate for history of arrhythmias or QT prolongation.
• Metabolic monitoring: check weight, glucose and lipid profiles regularly.
• Neurological review: watch for early signs of extrapyramidal symptoms.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks.
• Elderly patients: start at lower doses and monitor for sedation and falls.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Paliperidone palmitate can interact with several drug classes, requiring careful management.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., carbamazepine, rifampicin): may reduce plasma concentrations.
• Potent alpha‑adrenergic antagonists: increase risk of orthostatic hypotension.

Moderate Interactions (Monitor Closely):\n- Other antipsychotics: additive extrapyramidal effects.

• CNS depressants (e.g., benzodiazepines, opioids): enhanced sedation.
• Antihistamines with anticholinergic activity: may worsen dry mouth and constipation.
• QT‑prolonging agents: monitor ECG for additive cardiac effects.
• Lithium: increased risk of neurotoxicity.
• Antidiabetic drugs: monitor glucose as paliperidone may affect glycaemic control.